Results 221 to 230 of about 647,566 (296)

Sustainable bioplastics manufacturing from renewable sources

FEBS Open Bio, EarlyView.
Bioplastics are manufactured by using polymers from different bio‐based sources. These novel materials not only offer biodegradability but also possess various functional properties that make them suitable for diverse applications. Recent developments in the preparation of bioplastics are reported, highlighting the distinct properties of each type of ...
C. Valeria L. Giosafatto, Marika Avitabile, Michela Famiglietti, Talayeh Kordjazi, Marzieh Moosavi‐Nasab, Odile F. Restaino, Loredana Mariniello   +6 more
wiley   +1 more source

Perspectives and Experiences of Doctors and Pharmacists on the Clinical Use of Direct Oral Anticoagulants in Saudi Arabia. [PDF]

Pharmacy (Basel)
Aldossari DS, Latif K, Alsadoni AN, Alshehri OH, Binjathlan RI, Alenezy MM, Alshahrani TF, Lubbad HA, Alshamasi RS, Alanazi AK, Alotaibi RG, Arishi GI, Ali S.   +12 more
europepmc   +1 more source

Pioglitazone plus (−)‐epigallocatechin gallate: a novel approach to enhance osteogenic performance in aged bone marrow mesenchymal stem cells

FEBS Open Bio, EarlyView.
Aged human bmMSCs are seeded in the scaffold. Osteoblastic induction can slightly increase cell's bone‐forming activity to produce bone‐like tissues, shown as the sporadic xylenol orange‐stained spots (the lower left image). Notably, pioglitazone plus EGCG co‐treatment dramatically increases cell's bone‐forming activity and bone‐like tissue production (
Ching‐Yun Chen, Jia‐Ci Jhang, Chun‐Yi Peng, Quốc Cường Nguyễn, Feng‐Huei Lin, Hung‐Ming Wu, Shankung Lin   +6 more
wiley   +1 more source

Enzymatic degradation of biopolymers in amorphous and molten states: mechanisms and applications

FEBS Open Bio, EarlyView.
This review explains how polymer morphology and thermal state shape enzymatic degradation pathways, comparing amorphous and molten biopolymer structures. By integrating structure–reactivity principles with insights from thermodynamics and enzyme engineering, it highlights mechanisms that enable efficient polymer breakdown.
Anđela Pustak, Aleksandra Maršavelski
wiley   +1 more source

Exploring neurokinin-1 receptor antagonism for depression with structurally differentiated inhibitors. [PDF]

Exp Mol Med
Yoo H, Boo KJ, Nguyen LP, Hwang JI, Lee CS, Yang SH, Jeon SJ, Kim HR, Kim H.   +8 more
europepmc   +1 more source

The PFI-index according to Aasen for prognosis and course of polytraumatized patients [PDF]

, 1988
Baumgartner, I., Duswald, Karl-Heimo, Jochum, Marianne, Nast-Kolb, Dieter, Redl, H., Schlag, G., Schweiberer, Leonhard, Waydhas, Christian   +7 more
core  

Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP‐ribose) glycohydrolase inhibitor

FEBS Open Bio, EarlyView.
We analyzed alterations of PAR metabolism‐related proteins in PARG inhibitor‐resistant HCT116RPDD cells. Although PARG levels remained unchanged, HCT116RPDD cells exhibited reduced PARP1 and ARH3 expression and elevated PAR levels. Interestingly, HCT116RPDD cells exhibited slightly elevated intracellular NAD+/NADH and ATP levels. Our findings suggest a
Kaede Tsuda, Yoko Ogino, Akira Sato
wiley   +1 more source

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

FEBS Open Bio, EarlyView.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold, Janik Riese, Lancelot Seillier, Mark Kühnel, Julia Pannhausen, Charlotte O. J. Fröhlich, Christian Martin, Peter Boor, Matthias Saar, Danny D. Jonigk, Nadine T. Gaisa, Michael Rose   +11 more
wiley   +1 more source

Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Tian Z, Yang Y, Huang M, Fang Z, Mei J, Li Y, Tang L, Li Y, Li Y.   +8 more
europepmc   +1 more source